A U.S. appeals court said Eli Lilly may block Teva Pharmaceutical from selling a generic equivalent of its top-selling lung cancer drug Alimta.
Jim Cramer rattles off his take on caller favorite stocks, including this company owned by 'The Profit' himself.
Papa said he would consider selling some of Valeant's core businesses and assets against the wishes of some of its major shareholders.
Teva Pharmaceutical Industries, Mylan and others have received subpoenas and are cooperating, Bloomberg reported.
Here's what CNBC's Michael Santoli is watching into the closing bell.
Shares of Teva dropped 5 percent Tuesday after the company announced the head of its global generic medicine group will step down.
CNBC's Michael Santoli dives into the "worst to first" plays investors should be watching right now.
Jim Cramer’s revealing the hottest stock to own following Trump’s election win.
U.S. stock index futures indicated a slightly higher open Tuesday with investors focused on rising oil prices and the future policies of President-elect Donald Trump.
Some of the names on the move ahead of the open.
Shares of health insurers and hospitals got a lift Tuesday, but the rally doesn't extend to battered biotech and pharmaceutical stocks.
HSBC downgrades Teva Pharmaceuticals to hold from buy as investors are likely to "shoot first and ask questions later."
A daily look at the morning's key financial stories.
A number of companies including Mylan and Teva have disclosed subpoenas, Bloomberg reported.
CNBC's Dominic Chu reports on possible charges being filed by the Justice Department against some generic drugmakers, according to Bloomberg.
Biotech stocks have been taking a beating, and traders see especially bad things ahead for one company.
Discussing why options traders are cautious about Teva Pharmaceuticals with CNBC contributor Mike Khouw.
Every pharma CEO needs to step up and say these outrageous drug-price hikes are not OK, says former Medtronic CEO Bill George. e.
Sanofi and its U.S. partner Regeneron could win U.S. approval for their keenly awaited new eczema drug dupilumab.
It's "certainly clear that there will be negative impact going forward," but one analyst said the stock has already seen the worst.